Nautilus Biotechnology, Inc.
NAUT· Nasdaq
NAUTNautilus Biotechnology, Inc.
Filed Aug 10, 2021 · 10-Q · 41 days after period end · 0001808805-21-000007
| Metric | Q2 2021 | Q2 2020 |
|---|---|---|
| Net Income | -$10.71M | -$3.36M |
| EPS Diluted | -$0.19 | $0.00 |
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
Nautilus Biotechnology, Inc. · CIK 1808805 · Engraved from SEC EDGAR
ended Jun 30, 2021 · filed Aug 10, 2021 · 41 d after period end
